Prostate Cancer

A meta-analysis shows traditional pathology counts fail to predict which patients benefit from adding hormone therapy to postoperative radiation.

FDA approves Pluvicto with ARPI for PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer based on rPFS data.

A 10-year study of 3,477 patients reveals focal therapy offers high survival and low metastasis for localized prostate cancer with few side effects.

FDA approves capivasertib with abiraterone for PTEN-deficient mAPMN/S prostate cancer, requiring specific nursing education on intermittent dosing.

Dan Silver, PA-C, affirms patients with erectile dysfunction who’ve received prostate cancer treatment that it is possible to regain their erection.

The phase 2 ARACOG study is the first head-to-head randomized comparison of cognitive effects between the 2 androgen receptor pathway inhibitors.

A diabetes drug may help activate exercise-related metabolic pathways in patients with prostate cancer, offering insight into how to support metabolic health during treatment when physical activity is limited.

Abiraterone/prednisone plus olaparib improves survival outcomes vs monotherapy or sequential use in BRCA1/2- or ATM-altered mCRPC.

Explore safety and efficacy findings from KEYNOTE-B15/EV-304, LITESPARK-011, and more from the ASCO Genitourinary Cancers Symposium.

Adding 177Lu-PSMA-617 to ADT and an ARPI maintained health-related quality of life in patients with metastatic hormone-sensitive prostate cancer.

Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases.

Patients with PTEN-deficient metastatic hormone-sensitive prostate cancer had improved rPFS with capivasertib plus abiraterone.

The FDA has greenlit treatment with rucaparib for previously treated patients with BRCA-mutated metastatic castration-resistant prostate cancer.

The FDA has approved niraparib and abiraterone acetate with prednisone for the treatment of patients with BRCA2-mutated metastatic hormone-sensitive prostate cancer.

Patient-reported outcomes showed that health-related QOL stayed at baseline for patients with HRRM-positive mHSPC receiving a niraparib regimen.

The combination of apalutamide to carotuximab showed early signs of tolerability in patients with metastatic castration-resistant prostate cancer.

Gedatolisib-based combinations yielded encouraging responses in patients with mCRPC and HER2-positive metastatic breast cancer, early trial data show.

Oncologic therapies approved in June included indications in genitourinary, lung, hematologic, and head and neck cancers.

Patients with metastatic CRPC who maintained PSMA expression had a median OS of 14.5 months with 177Lu-PSMA-617 retreatment.

Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane chemotherapy.

The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.

The combination of niraparib with abiraterone acetate and prednisone (AAP) boosted rPFS vs AAP plus placebo in HRR-mutated mCSPC.

The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC lacking HRR mutations.

Use of the 1.5T Elekta Unity MR-Linac was associated with reduced rates of erectile dysfunction at 6, 12, and 18 months in patients with prostate cancer.

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.